8:00am Registration, Morning Coffee & One-to-One Meetings
8:15 Chairperson’s Remarks & Recap of Monday
Stuart Kliman, J.D., Head, Pharmaceuticals Practice Area, Vantage Partners
8:30 KEYNOTE PRESENTATION
Sponsored by
Leadership’s Role in Implementing an Alliance Dependent Business Strategy
Stuart Kliman, J.D., Head, Pharmaceuticals Practice Area, Vantage Partners
While many organizations have an Alliance Management function, and even those without the function, few actually have an alliance management capability. This gap is most often caused by a lack of leadership. This presentation will discuss why organizations have failed to provide the kind of leadership necessary for systematic alliance success, what such leadership would entail, and how folks worried about alliance management can effect real change.
SHARED 'LEARNINGS' FROM DIFFERENT
TYPES OF ALLIANCES CONTINUED
9:15 Pharma and Academia Example
Establishing Partnership-Collaboration between Academia and Big Pharma
Qing Liu, Ph.D., Associate Director of Strategic Alliances, Harvard Stem Cell Institute
The collaboration between Harvard Stem Cell Institute and GlaxoSmithKline is one of the largest between academia and big pharma. This talk will present the lessons learned from effectively managing this alliance. Participants will learn how to effectively manage alliances between big pharma and academia, how best to communicate within and outside complex teams, and how to maintain healthy status of a partnership over long periods of time.
9:45 Private Sector and Academia Example
Building Partnerships upon Measurable Win-Win Approaches
David Gobey, B.Sc., B.A., M.Sc., Director, Food and Agricultural Technology Commercialization and Economic Development Program (ATECH), The Ohio State University
We have built a program, on a university campus, that has sped products to market for our clients. After three years of operation, the initial seed capital of $600K has grown into annual revenues of over $10 million. Alliances are not built on IP, license “deals” and royalties. This talk will explore how we define and build private sector/academic partnerships based upon measurable win-win approaches.
10:15 Coffee Break, Exhibit Viewing & One-to-One Meetings
10:45 Clinical and Diagnostic Example partnership and Commercialization Models at National Jewish Health
Preveen Ramamoorthy, Ph.D., Director, Molecular Diagnostics, Advanced Diagnostic Laboratories, Assistant Professor, Department of Medicine, National Jewish Health
National Jewish Health is at the forefront of developing and implementing personalized medicine strategies in Allergy, Asthma, COPD, Immunological diseases, Respiratory infections and Lung cancer. A vital ingredient to the success of personalized medicine is building a self-contained translational research ecosystem followed by discovery, development, validation and implementation of good molecular diagnostics and/or other diagnostic tests. To develop and commercialize diagnostics we identify and validate in-house or external biomarkers into clinical diagnostic tests, then enter into partnerships with national reference laboratories, diagnostics companies/drug development companies.
11:15 Academia and Commercialized Diagnostic Example
Mining the Human Proteome: Cancer Biomarker Discovery
Roopali Roy, Ph.D., Instructor, Moses Laboratory, Vascular Biology Program, Department of Surgery, Children's Hospital, Harvard Medical School
11:45 Public-Private Partnership Example
Public-Private Partnership Models in Product Development and Commercialization
Tala V. de los Santos, M.S., M.B.A., Commercialization Officer II, Commercialization and Corporate Partnerships, PATH
PATH is an international nonprofit organization that creates sustainable, culturally relevant solutions, enabling communities worldwide to break longstanding cycles of poor health. By collaborating with diverse public- and private-sector partners, we help provide appropriate health technologies and vital strategies that change the way people think and act.
12:15 Alliance Management ThemeSponsored by
Partnering for Multi-Segment Market Approaches Incorporating NDI, Medical Food and Prescription Drugs
Tina Sampalis, M.D., Ph.D., President, Acasti Pharma, Inc.
Acasti develops proprietary compositions based on GMP manufactured novel active ingredients researched and validated safe and effective alternatives for the cardiometabolic and neurological markets as medical foods, over the counter or prescription drugs, either as stand-alone or in combination to existing products. This talk will describe Acasti Pharma’s corporate strategy of seeking alliances for its new product development while providing innovative in-out licensing agreements.
12:30 CHI Hosted Luncheon
DEVELOPING THE ALLIANCE MANAGEMENT INFRASTRUCTURE
The Congress talks so far have focused on industry trends and strategic aspects of collaborations, deal making strategies, and a variety of partnership models. The talks in this session now focus on the tactical aspects of alliance implementation after the deal is signed.
1:45 Transversal Alliance Management: Developing a Successful Internal Infrastructure to Manage Alliance Capability
Kimberly Brue, Director, Alliance Management, Prospective & Strategic Initiatives, Sanofi Aventis
Chris Scirrotto, Manager, Alliance Management, Sanofi Pasteur
We know that to have successful alliances, you need a successful internal infrastructure. Using sanofi pasteur as an example, this presentation provides detailed information and invites discussion around how to map your internal alliance support network and facilitate better interactions with partners - a.k.a. “Transversal AM”. Attendees across all industries will learn how to identify internal issues, map resolutions, and implement operational- and organizational-level remediations to increase their capability of managing alliances.
2:15 Alliance Factors for Launching and Maintaining an Alliance Management Function in Biotechnology
Jamie J. Breslin, Ph.D., Manager, Alliance Management, PTC Therapeutics
One of the fastest growing trends for businesses today is the increasing number of strategic alliances. Alliances are becoming a tool for expanding the reach of a company without committing to internal growth. Building organizational collaboration competency is crucial in order to extract the most value from a strategic alliance. This talk will provide an overview of determining when your organization is ready to build an alliance management function and what factors influence the success of establishing and maintaining the function.
2:45 Managing Alliances without an Alliance Management Function-Challenges and Opportunities
Gerd G. Kochendoerfer, Ph.D., Senior Director, Project Management, Depomed
Alliances are key to the success of small specialty pharma and biotech companies. Typically, however, such companies have not formalized the structures and processes that support alliances in larger organizations, rather relying on existing individual talent, experience and improvisation. Whereas each alliance has different needs, certain best practices can mitigate the resulting risk to the alliance. Through multiple case studies of both successful and underperforming alliances, the presentation aims to better prepare smaller organizations for a productive collaboration.
3:15 Refreshment Break, Exhibit Viewing & One-to-One Meetings
3:30 Migration from a Decentralized to Centralized Model of Alliance Management: Attainment of Organizational Buy-in for New Roles, Tools, and Systems
Joel Edwards, Director, Alliance Management, Isis Pharmaceuticals
This talk will outline the implementation plan utilized to migrate from a decentralized to centralized alliance management capability at Isis Pharmaceuticals. The efforts invested to centralize the group have lead to significant operational enhancements and greater alliance productivity. The design, testing, and implementation of new alliance management roles and tools will be discussed. The presentation will also include key considerations for organizing and prioritizing the alliance portfolio.
4:00 Differences between Alliance and Project Management
Ailsa Mendez, Director, Project Governance, Functional Genetics
4:30 Close of AMS